Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB)
The initial members of Forty Seven’s SAB include:
James Allison, Ph.D., Chair, Department of Immunology, Director, Parker Institutefor Cancer Research, and Executive Director, Immunotherapy Platform at the University of TexasMD Anderson Cancer Center; Winner, 2018 Nobel Prize in Physiology or Medicine Ronald Levy, M.D., Professor of Medicine at Stanford University School of Medicine
- Padmanee Sharma, M.D., Ph.D., Professor,
Department of Genitourinary Medical Oncologyand Department of Immunology, Division of Cancer Medicineat the University of Texas MD Anderson Cancer Center, Scientific Director, Immunotherapy Platform and Co-Director of the Parker Institute for Cancer Immunotherapyat MD Anderson Cancer Center Louis Weiner, M.D., Director, Georgetown Lombardi Comprehensive Cancer Center and Professor and Chair, Department of Oncology, at Georgetown University Medical Center
“We are pleased to welcome these distinguished physicians and researchers to Forty Seven’s SAB,” said
“As a medical oncologist and immunotherapy researcher, I am committed to exploring new approaches to safely and more effectively address the unmet needs of cancer patients,” said
Dr. Allison is the Chair of the
Padmanee Sharma, M.D., Ph.D.
Dr. Sharma is a Professor in the
She is a medical oncologist and immunologist, and a leading clinical investigator in immunotherapy trials, which allows her to further investigate immune responses and pathways that are critical for eliciting anti-tumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field, including MD Anderson Physician-Scientist Award, Prostate Cancer Foundation Challenge Award, MD Anderson Team Science Award, Emil-Frei Award for
Dr. Weiner is the Director of the
Forward Looking Statements:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These statements include those related to the advancement and clinical development of 5F9; the potential of 5F9 in multiple oncology indications and Forty Seven’s intention to implement an efficient, robust development program for 5F9. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Forty Seven develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Forty Seven's stock price. Additional information concerning these and other risk factors affecting Forty Seven's business can be found in Forty Seven's periodic filings with the
For more information please visit www.fortyseveninc.com or contact email@example.com.
For journalist inquiries please contact
For investor inquiries please contact
Source: Forty Seven, Inc.